Literature DB >> 14977862

Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.

Takashi Nozawa1, Shigeki Sugiura, Miki Nakajima, Akihiko Goto, Tsuyoshi Yokoi, Jun-Ichi Nezu, Akira Tsuji, Ikumi Tamai.   

Abstract

Troglitazone is a thiazolidinedione insulin sensitizer drug that is metabolized mainly to a sulfate conjugate (M-1) in humans. It was reported to cause hepatotoxicity, although the cause has not been fully clarified. The objective of this study was to identify whether organic anion transporting polypeptide (OATP) transporters expressed at the basolateral membrane of human hepatocytes participate in troglitazone-associated hepatotoxicity. When OATP-B, OATP-C, or OATP8 was expressed in Xenopus oocytes, the transporter-mediated uptake into oocytes of troglitazone sulfate conjugate and the inhibitory effects of thiazolidinediones and the metabolites of troglitazone on estrone-3-sulfate transport were measured. M-1 was transported well by OATP-C but was not transported by OATP-B. OATP8 showed weak, but not statistically significant, transport of M-1. M-1 exhibited a strong inhibitory effect on estrone-3-sulfate transport by OATP-C and OATP8, suggesting a higher affinity than other thiazolidinediones and the metabolites of troglitazone, glucuronide conjugate and quinone metabolite. In conclusion, the sulfate conjugate of troglitazone has a higher affinity for OATPs than troglitazone itself or other metabolites. Since OATP transporters are important in the hepatic handling of bile acids, bilirubin, and other endogenous anionic compounds, M-1 may disturb the hepatic influx and efflux transport of these endogenous molecules across the basolateral membranes. Moreover, OATP-C may be involved in the hepatic toxicity of troglitazone through the inhibitory action of M-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977862     DOI: 10.1124/dmd.32.3.291

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  19 in total

Review 1.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.

Authors:  Kyoung-Ah Kim; Pil-Whan Park; Kyong Rae Kim; Ji-Young Park
Journal:  Br J Clin Pharmacol       Date:  2006-09-19       Impact factor: 4.335

Review 3.  Pharmacogenomics of human OATP transporters.

Authors:  Jörg König; Annick Seithel; Ulrike Gradhand; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-09       Impact factor: 3.000

Review 4.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.

Authors:  Bani Tamraz; Hisayo Fukushima; Alan R Wolfe; Rüdiger Kaspera; Rheem A Totah; James S Floyd; Benjamin Ma; Catherine Chu; Kristin D Marciante; Susan R Heckbert; Bruce M Psaty; Deanna L Kroetz; Pui-Yan Kwok
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

6.  Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035.

Authors:  Minoru Tsuda-Tsukimoto; Tomoji Maeda; Takashi Iwanaga; Toshiyuki Kume; Ikumi Tamai
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

Review 7.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

8.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

Review 9.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

10.  Predominant contribution of rat organic anion transporting polypeptide-2 (Oatp2) to hepatic uptake of beta-lactam antibiotics.

Authors:  Masanori Nakakariya; Taiki Shimada; Masanori Irokawa; Hiroyuki Koibuchi; Takashi Iwanaga; Hikaru Yabuuchi; Tomoji Maeda; Ikumi Tamai
Journal:  Pharm Res       Date:  2007-09-22       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.